Mary Beth Rios

Statistics

Publications

102

Citations

10.1K

H-Index

Active since

1992

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Leukemia and Lymphoma Society

Mary Beth Rios is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, chronic myeloid leukemia therapy, and hematology.

Publications per year

1992–2020

102

Publications

102

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen et al. · The Lancet Oncology · 2012 · 412 citations

Medicine, Immunology, Oncology +14

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien et al. · Blood · 2003 · 391 citations · Full text

Medicine, Hematology, Pharmacotherapy +8

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

Elias Jabbour, Hagop M. Kantarjian, Dan Jones et al. · Leukemia · 2006 · 387 citations

Medicine, Hematology, Oncology +11

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Hagop M. Kantarjian, Susan O’Brien, Elias Jabbour et al. · Blood · 2012 · 338 citations · Full text

Medicine, Hematology, Oncology +5

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien et al. · Blood · 2002 · 308 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +6

1–5 of 102